The list, which could be expanded over time, will eliminate up to 25% of these reauthorization requirements and accounts for ...

Achmea Investment Management B.V. significantly reduced its position in Regeneron Pharmaceuticals by 90.5% in the fourth ...

In the current session, Regeneron Pharmaceuticals Inc. REGN is trading at $672.39, after a 0.89% decrease. Over the past month, the stock decreased by 0.97%, and in the past year, by 30.36%. With ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc.

Jim Cramer said in response to a question during a recent program on CNBC that he’d recommend investors own Regeneron ...

Intact Investment Management Inc. bought 500 shares of Regeneron Pharmaceuticals, worth $356,000, in the 4th quarter. Several ...

For Regeneron Pharmaceuticals, average sales revenue over the last 5 years has been $15.84 Billion, so in the context of the Graham analysis the stock has impressive sales revenue. Originally the ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently presented positive results from its Dupixent trial for bullous pemphigoid at the AAD Annual Meeting, demonstrating its ongoing strides in addressing ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

The S&P 500 dropped 2.7% on Monday, March 10, as U.S. tariffs and government job cuts heightened economic uncertainty and ...

Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...

Jones Financial Companies Lllp increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) ...